Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Möhler T[au]:

Reply. Proebstle TM et al. J Vasc Surg Venous Lymphat Disord. (2016)

A two-cohort feasibility study on polyglycolic acid yarn implantation for abolition of saphenous vein reflux. Proebstle TM et al. J Vasc Surg Venous Lymphat Disord. (2018)

Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial. Huhn S et al. Bone Marrow Transplant. (2017)

Search results

Items: 28

1.

Measuring the accuracy of propofol target-controlled infusion (TCI) before and after surgery with major blood loss.

Mohler T, Welter J, Steurer M, Neumann L, Zueger M, Kraemer T, Dullenkopf A.

J Clin Monit Comput. 2019 Jan 22. doi: 10.1007/s10877-019-00261-8. [Epub ahead of print]

PMID:
30671895
2.

A two-cohort feasibility study on polyglycolic acid yarn implantation for abolition of saphenous vein reflux.

Proebstle TM, Kleis-Fischer B, Möhler T, Goeckeritz O, Franklin IJ, Almeida JI.

J Vasc Surg Venous Lymphat Disord. 2018 Jan;6(1):41-47.e1. doi: 10.1016/j.jvsv.2017.07.007. Epub 2017 Oct 6.

PMID:
28993089
3.

Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial.

Huhn S, Weinhold N, Nickel J, Pritsch M, Hielscher T, Hummel M, Bertsch U, Huegle-Doerr B, Vogel M, Angermund R, Hänel M, Salwender HJ, Weisel K, Dürig J, Görner M, Kirchner H, Peter N, Graeven U, Lordick F, Hoffmann M, Reimer P, Blau IW, Jauch A, Dembowsky K, Möhler T, Wuchter P, Goldschmidt H.

Bone Marrow Transplant. 2017 Aug;52(8):1194-1198. doi: 10.1038/bmt.2017.91. Epub 2017 May 15. No abstract available.

4.

Reply.

Proebstle TM, Möhler T.

J Vasc Surg Venous Lymphat Disord. 2016 Jul;4(3):380-1. doi: 10.1016/j.jvsv.2016.05.001. No abstract available.

PMID:
27318062
5.

A longitudinal single-center cohort study on the prevalence and risk of accessory saphenous vein reflux after radiofrequency segmental thermal ablation of great saphenous veins.

Proebstle TM, Möhler T.

J Vasc Surg Venous Lymphat Disord. 2015 Jul;3(3):265-9. doi: 10.1016/j.jvsv.2014.10.001. Epub 2014 Dec 6.

PMID:
26992304
6.
7.

Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine.

Meissner T, Seckinger A, Rème T, Hielscher T, Möhler T, Neben K, Goldschmidt H, Klein B, Hose D.

Clin Cancer Res. 2011 Dec 1;17(23):7240-7. doi: 10.1158/1078-0432.CCR-11-1628. Epub 2011 Oct 10.

8.

[Erythematosus plaques and nodules in a 50-year old patient with rheumatoid arthritis. Interstitial granulomatous dermatitis with arthritis].

Rietz S, Möhler T, Bräuninger W, Steinbrink K.

J Dtsch Dermatol Ges. 2011 Jan;9(1):67-9. doi: 10.1111/j.1610-0387.2010.07534.x. German. No abstract available.

PMID:
21166781
9.

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.

Hose D, Rème T, Hielscher T, Moreaux J, Messner T, Seckinger A, Benner A, Shaughnessy JD Jr, Barlogie B, Zhou Y, Hillengass J, Bertsch U, Neben K, Möhler T, Rossi JF, Jauch A, Klein B, Goldschmidt H.

Haematologica. 2011 Jan;96(1):87-95. doi: 10.3324/haematol.2010.030296. Epub 2010 Sep 30.

10.

Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.

Seckinger A, Meissner T, Moreaux J, Goldschmidt H, Fuhler GM, Benner A, Hundemer M, Rème T, Shaughnessy JD Jr, Barlogie B, Bertsch U, Hillengass J, Ho AD, Pantesco V, Jauch A, De Vos J, Rossi JF, Möhler T, Klein B, Hose D.

Oncogene. 2009 Nov 5;28(44):3866-79. doi: 10.1038/onc.2009.257. Epub 2009 Aug 31.

11.

Induction of angiogenesis by normal and malignant plasma cells.

Hose D, Moreaux J, Meissner T, Seckinger A, Goldschmidt H, Benner A, Mahtouk K, Hillengass J, Rème T, De Vos J, Hundemer M, Condomines M, Bertsch U, Rossi JF, Jauch A, Klein B, Möhler T.

Blood. 2009 Jul 2;114(1):128-43. doi: 10.1182/blood-2008-10-184226. Epub 2009 Mar 18.

12.

Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma.

Hose D, Rème T, Meissner T, Moreaux J, Seckinger A, Lewis J, Benes V, Benner A, Hundemer M, Hielscher T, Shaughnessy JD Jr, Barlogie B, Neben K, Krämer A, Hillengass J, Bertsch U, Jauch A, De Vos J, Rossi JF, Möhler T, Blake J, Zimmermann J, Klein B, Goldschmidt H.

Blood. 2009 Apr 30;113(18):4331-40. doi: 10.1182/blood-2008-09-178350. Epub 2009 Jan 26.

13.

CD200 is a new prognostic factor in multiple myeloma.

Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E, Moine P, Bourin P, Moos M, Corre J, Möhler T, De Vos J, Rossi JF, Goldschmidt H, Klein B.

Blood. 2006 Dec 15;108(13):4194-7. Epub 2006 Aug 31. Erratum in: Blood. 2007 Apr 1;109(7):2717.

14.

[Multiple myeloma. Diagnosis and therapy].

Goldschmidt H, Cremer FW, Möhler TM, Ho AD.

Internist (Berl). 2003 May;44(5):599-600, 603-16; quiz 617-8. German.

PMID:
12966788
15.

Inhibition of angiogenesis by non-toxic doses of temozolomide.

Kurzen H, Schmitt S, Näher H, Möhler T.

Anticancer Drugs. 2003 Aug;14(7):515-22. Review.

PMID:
12960735
16.

Restricted T-cell receptor repertoire in melanoma metastases regressing after cytokine therapy.

Willhauck M, Scheibenbogen C, Pawlita M, Möhler T, Thiel E, Keilholz U.

Cancer Res. 2003 Jul 1;63(13):3483-5.

17.

Inhibition of angiogenesis in vitro by alphav integrin-directed antisense oligonucleotides.

Kronenwett R, Gräf T, Nedbal W, Weber M, Steidl U, Rohr UP, Möhler T, Haas R.

Cancer Gene Ther. 2002 Jul;9(7):587-96.

19.
20.

Regulation of interleukin-8 mRNA expression and protein secretion in a melanoma cell line by tumour necrosis factor-alpha and interferon-gamma.

Möhler T, Scheibenbogen C, Häfele J, Willhauck M, Keilholz U.

Melanoma Res. 1996 Aug;6(4):307-11.

PMID:
8873050
21.

T-cell receptor beta variable region diversity in melanoma metastases after interleukin 2-based immunotherapy.

Willhauck M, Möhler T, Scheibenbogen C, Pawlita M, Brossart P, Schmier JW, Keilholz U.

Clin Cancer Res. 1996 Apr;2(4):767-72.

22.

A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood.

Brossart P, Schmier JW, Krüger S, Willhauck M, Scheibenbogen C, Möhler T, Keilholz U.

Cancer Res. 1995 Sep 15;55(18):4065-8.

23.

Addition of dacarbazine or cisplatin to interferon-alpha/interleukin-2 in metastatic melanoma: toxicity and immunological effects.

Keilholz U, Scheibenbogen C, Möhler T, Brossart P, Maclachlan D, Geueke AM, Jochim A, Hunstein W.

Melanoma Res. 1995 Aug;5(4):283-7.

PMID:
7496166
24.

Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load.

Scheibenbogen C, Möhler T, Haefele J, Hunstein W, Keilholz U.

Melanoma Res. 1995 Jun;5(3):179-81.

PMID:
7640519
25.

Restriction of T cell receptor V beta repertoire in melanoma metastasis responding to immunotherapy.

Möhler T, Willhauck M, Scheibenbogen C, Pawlita M, Bludau H, Brossart P, Hunstein W, Keilholz U.

Melanoma Res. 1995 Apr;5(2):129-32.

PMID:
7620341
26.

Interleukin-2-based immunotherapy and chemoimmunotherapy in metastatic melanoma.

Keilholz U, Scheibenbogen C, Brossart P, Möhler T, Tilgen W, Hunstein W.

Recent Results Cancer Res. 1995;139:383-90.

PMID:
7597305
27.

Detection of residual tumor cells in patients with malignant melanoma responding to immunotherapy.

Brossart P, Keilholz U, Scheibenbogen C, Möhler T, Willhauck M, Hunstein W.

J Immunother Emphasis Tumor Immunol. 1994 Jan;15(1):38-41.

PMID:
8110729
28.

Hematogenous spread of malignant melanoma cells in different stages of disease.

Brossart P, Keilholz U, Willhauck M, Scheibenbogen C, Möhler T, Hunstein W.

J Invest Dermatol. 1993 Dec;101(6):887-9.

Supplemental Content

Loading ...
Support Center